MedTrace Logo

Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia

NCT02307201 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1114

Last updated 2017-02-01

No results posted yet for this study

Summary

There is no evidence that patients receiving magnesium sulfate before birth are required to maintain the drug for 24 hours. Therefore the investigators will have a randomized clinical study in patients with severe preeclampsia who have been treated with impregnation of magnesium sulphate and at least eight hours have received the drug before birth. If the patient agrees and signs the consent is randomized to: 1-receive sulfate for 24 hours postpartum as usual or, 2- not receiving the postpartum magnesium sulfate or other anticonvulsant drugs. This study can be conducted in 12 maternity latin america.

Conditions

  • Post Partum Severe Preeclampsia

Interventions

DRUG

Magnesium Sulfate

The patient will receive magnesium sulfate for 24 hours postpartum

Sponsors & Collaborators

  • Complejo Hospitalario Dr. Arnulfo Arias Madrid

    lead OTHER

Principal Investigators

  • Paulino Vigil De Gracia · Complejo Hospitalario Dr. Arnulfo Arias Madrid

  • Jack Ludmir, MD · School of medicine, Pennsylvania Hospital. University de Pennsylvania. Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Dominican Republic
  • Ecuador
  • El Salvador
  • Panama
  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02307201 on ClinicalTrials.gov